Financials in USD. Standardized financial statements.
A compact view of how Advanced Biomedical Technologies, Inc. turns revenue into operating income and net income.
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $270,991 | $171,192 | $123,587 | $11,657 | $0 | $0 | $0 | $0 | $0 | $0 |
| Revenue Growth? | +58.3% | +38.5% | +960.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $49,112 | $77,897 | $51,817 | $7,596 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit? | $221,879 | $93,295 | $71,770 | $4,061 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Margin? | +81.9% | +54.5% | +58.1% | +34.8% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $401,764 | $488,155 | $518,394 | $608,799 | $634,017 | $403,613 | $461,329 | $605,193 | $617,754 | $718,744 |
| Operating Income? | -$179,880 | -$394,860 | -$446,624 | -$604,738 | -$634,017 | -$403,613 | -$461,329 | -$605,193 | -$617,754 | -$718,744 |
| EBITDA? | -$166,007 | -$367,435 | -$282,694 | -$601,264 | -$636,456 | -$420,233 | -$445,872 | -$574,742 | -$591,114 | -$692,543 |
| Income Before Tax | -$515,485 | -$729,441 | -$672,000 | -$948,820 | -$953,320 | -$691,600 | -$724,737 | -$862,854 | -$827,756 | -$890,343 |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$515,485 | -$729,441 | -$672,000 | -$948,820 | -$953,320 | -$691,600 | -$724,737 | -$862,854 | -$827,756 | -$890,343 |
| EPS? | $-0.01 | $-0.01 | $-0.01 | $-0.01 | $-0.01 | $-0.01 | $-0.01 | $-0.02 | $-0.01 | $-0.02 |
| Diluted EPS? | $-0.01 | $-0.01 | $-0.01 | $-0.01 | $-0.01 | $-0.01 | $-0.01 | $-0.02 | $-0.01 | $-0.02 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality